Ipsen CEO Shares Letter with FOP Community

On August 16, 2023, Ipsen received approval from the U.S. Food & Drug Administration for palovarotene capsules as a treatment for FOP in females aged 8 and up and males aged 10 and up living in the United States. Where approved as a treatment for FOP, palovarotene capsules are now known by the brand name SohonosTM.

In response to the approval, Ipsen CEO David Loew shares this letter with the FOP community. 

Make a Difference

Donate Connect Fundraise

Already a Member? Sign In

Sign Up for FOP Connection, Our Monthly eNewsletter